LOS ANGELES, May 31, 2016 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that
Olivia Ware, Chief Commercial Officer, and David Haen, Vice
President of Business Development and Investor Relations, will present a corporate update at the Jefferies 2016 Global Healthcare
Conference on Tuesday, June 7th at 4:30 p.m. Eastern Time
in New York City.
A live and archived webcast of the presentation will be available at http://wsw.com/webcast/jeff97/cytr.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is
focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin,
and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016. CytRx is also expanding its pipeline
of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™
(Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology
and linker technology for the development of a new class of anti-cancer therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking statements, including risks relating to the outcome,
timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform,
the outcome, timing or results of CytRx's clinical testing of aldoxorubicin, the risk that any future pre-clinical or human
testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds,
risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial
quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or
strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3
clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds
based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers
and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date
of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date
the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor Relations
(310) 826-5648, ext 304
dhaen@cytrx.com
Investor Relations:
Alexander Capital, LP
(855) 288-ALEX (2539)
cytrx@alexandercapitallp.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytrx-to-present-at-jefferies-2016-global-healthcare-conference-300276730.html
SOURCE CytRx Corporation